What is Zacks Research's Estimate for CRL Q2 Earnings?

Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) - Stock analysts at Zacks Research dropped their Q2 2026 earnings per share (EPS) estimates for Charles River Laboratories International in a note issued to investors on Thursday, April 10th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $2.46 per share for the quarter, down from their prior forecast of $2.67. The consensus estimate for Charles River Laboratories International's current full-year earnings is $9.36 per share.

CRL has been the topic of a number of other research reports. Robert W. Baird decreased their target price on Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a research report on Thursday, February 20th. Mizuho decreased their price target on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. JPMorgan Chase & Co. cut their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a research report on Thursday, February 20th. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $190.00 to $170.00 in a report on Friday, March 21st. Finally, Redburn Atlantic raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective on the stock in a report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $182.00.

Charles River Laboratories International Price Performance

Shares of CRL stock traded up $1.64 during trading hours on Monday, reaching $105.89. The company's stock had a trading volume of 1,658,424 shares, compared to its average volume of 891,981. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International has a fifty-two week low of $91.86 and a fifty-two week high of $254.15. The company has a market capitalization of $5.20 billion, a price-to-earnings ratio of 705.91, a PEG ratio of 4.54 and a beta of 1.45. The firm's 50 day simple moving average is $151.07 and its 200-day simple moving average is $174.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to analysts' expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business's revenue for the quarter was down 1.1% compared to the same quarter last year. During the same period in the previous year, the company earned $2.46 EPS.

Institutional Investors Weigh In On Charles River Laboratories International

A number of hedge funds have recently added to or reduced their stakes in CRL. Fiduciary Financial Group LLC grew its position in shares of Charles River Laboratories International by 3.9% during the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock worth $310,000 after buying an additional 63 shares during the period. Pinnacle Bancorp Inc. grew its holdings in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after purchasing an additional 65 shares during the period. M&T Bank Corp increased its stake in Charles River Laboratories International by 3.4% in the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company's stock valued at $394,000 after purchasing an additional 66 shares in the last quarter. Cornerstone Investment Partners LLC raised its holdings in shares of Charles River Laboratories International by 3.7% during the fourth quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company's stock valued at $358,000 after purchasing an additional 69 shares during the period. Finally, Metis Global Partners LLC boosted its position in shares of Charles River Laboratories International by 4.4% during the 4th quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company's stock worth $318,000 after purchasing an additional 72 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Charles River Laboratories International news, COO Birgit Girshick purchased 1,514 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was purchased at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the acquisition, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the business's stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).